SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Avila Therapeutics Announces FDA Allowance of Partner Clovis Oncology’s IND Application for CO-1686, an Oral EGFR Mutant-Selective Inhibitor, Triggers $4 Million Milestone Payment to Avila